

THE UNIVERSITY OF MICHIGAN  
REGENTS COMMUNICATION

ACTION REQUEST

Subject: Project Agreements with the University of Michigan

Action Requested: Authorization to enter into or amend Agreements

Preamble:

Statutory conflicts of interest situations were identified by the Office of Research and Sponsored Projects while reviewing Proposal Approval Forms that then triggered a review by the Medical School Conflict of Interest Board and/or the UMOR Conflict of Interest Review Committee. Plans for management of the possible risks associated with the conflicts of interest will be developed and approved by the Board and/or Committee and may require agreement by the parties involved at time of award.

These proposed project (e.g., research, sponsored activity, and/or subcontract) agreements (“Agreement”) and/or amendments to Agreements (“Amendments”) fall under the State of Michigan Conflict of Interest Statute because University of Michigan (“University”) employees have activities, relationships, or interests in the companies as described in Attachment A. The law permits such Agreements provided they are disclosed to the Board of Regents (“Regents”) of the University and approved in advance by a 2/3 vote.

Agreement Terms:

The terms of the Agreements and/or Amendments conform to University policy. The funding support will not exceed the amount reported in Attachment A for each Agreement and/or Amendment. Since projects are often amended, these Agreements and/or Amendments include provisions for changes in time and scope. University procedures for approval of these changes will be followed and additional conflict of interest review will be done as appropriate.

Impact of the Agreement:

The Agreements and/or Amendments will provide support of investigator’s effort to use their expertise and University laboratories, as well as other University resources, to execute the projects as reported in Attachment A.

Recommendations:

These matters have been reviewed and approved by the Medical School Conflict of Interest Board and/or the UMOR Conflict of Interest Review Committee. In light of this disclosure and our finding that the Agreements and Amendments were negotiated in conformance with standard University practices, I recommend that the Board of Regents approve the University’s entering into or amending the Agreements referenced in Attachment A.

Respectfully submitted,

A handwritten signature in black ink, appearing to read 'Rebecca Cunningham', written in a cursive style.

Rebecca Cunningham  
Vice President for Research

May 2022

## Attachment A

### Project #1

<b>STTR Phase I Subcontract Agreement between the University and Arbor Batteries LLC Reviewed by the UMOR Conflict of Interest Review Committee</b>	
<b><u>Project Information</u></b>	
<b>Title:</b> Li-ion Batteries with 3D Structured Anodes for Increased Safety and Energy Density	<b>U-M Project ID:</b> 22-PAF04587
<b>Direct Sponsor:</b> Arbor Batteries LLC	<b>Prime Sponsor:</b> Department of Energy
<b>Principal Investigator/Department:</b> Neil Dasgupta, Mechanical Engineering	
<b>Project Duration:</b> One (1) Year	<b>Funding Support:</b> \$100,000
<b>Purpose:</b> The purpose of this project is to develop and optimize a laser ablation process to 3-D structure the electrodes.	
<b><u>University Employee; University Title; Relationship with Arbor Batteries LLC</u></b>	
<ul style="list-style-type: none"><li>• Neil Dasgupta; Associate Professor, Mechanical Engineering; Partial Owner</li><li>• Jeff Sakamoto; Associate Professor, Mechanical Engineering; Partial Owner</li></ul>	

### Project #2

<b>STTR Phase I/II Subcontract Agreement between the University and GeneToBe, LLC Reviewed by the Medical School Conflict of Interest Board</b>	
<b><u>Project Information</u></b>	
<b>Title:</b> Repurposing SGLT inhibitor drugs for cystic fibrosis liver disease - STTR Fast Track	<b>U-M Project ID:</b> 22-PAF05727
<b>Direct Sponsor:</b> GeneToBe, LLC	<b>Prime Sponsor:</b> National Institutes of Health
<b>Principal Investigator/Department:</b> Jie Xu, Internal Medicine-Cardiology	
<b>Project Duration:</b> Three (3) Years	<b>Funding Support:</b> \$782,000
<b>Purpose:</b> The purpose of this project is to test the hypothesis that sodium glucose cotransporter (SGLC) inhibitor drugs are benefits for cystic fibrosis individuals through improving their liver conditions.	
<b><u>University Employee; University Title; Relationship with GeneToBe, LLC</u></b>	
<ul style="list-style-type: none"><li>• Yuqing Chen; Professor, Cardiovascular Medicine; Partial Owner</li><li>• Jie Xu; Research Associate Professor, Internal Medicine-Cardiology; Partial Owner</li></ul>	

### Project #3

**SBIR Phase II Subcontract Agreement between the University and H3D, Inc.  
Reviewed by the UMOR Conflict of Interest Review Committee**

#### Project Information

**Title:** Non-Intrusive Mercury Detection and Measurement

**U-M Project ID:** 22-PAF06574

**Direct Sponsor:** H3D, Inc.

**Prime Sponsor:** Department of Energy

**Principal Investigator/Department:** Igor Jovanovic, Nuclear Engineering & Radiological Sciences (NERS)

**Project Duration:** Two (2) Years

**Funding Support:** \$12,800

**Purpose:** The purpose of this project is to develop an imaging spectrometer that can detect and localize mercury via excitation by external neutron source.

#### University Employee; University Title; Relationship with H3D, Inc.

- Zhong He; Professor, NERS; Partial Owner
- Yuefeng Zhu; Associate Research Scientist, NERS; Partial Owner

### Project #4

**Amendment to STTR Phase I Subcontract Agreement between the University and iReprogram, LLC  
Reviewed by the Medical School Conflict of Interest Board**

#### Project Information

**Title:** Autologous Hematopoietic Stem Cell Production to End Graft-Versus-Host Disease

**U-M Project ID:** 22-PAF06252

**Direct Sponsor:** iReprogram, LLC

**Prime Sponsor:** National Science Foundation

**Principal Investigator/Department:** Indika Rajapakse, Computational Medicine and Bioinformatics

**Agreement Initiated:** February 15, 2021

**Project Duration:** Nine (9) months

**Funding Support:** \$140,043

**Additional Time:** Nine (9) months

**Additional Funding Support:** \$25,000

**Purpose:** The purpose of this amendment is to add additional funds and time so that the Rajapakse lab may perform research on the reprogramming capability of transcription factors sets predicted to generate hematopoietic stem cells (HSCs).

#### University Employee; University Title; Relationship with iReprogram, LLC

- Indika Rajapakse; Associate Professor, Computational Medicine and Bioinformatics; Partial Owner
- Lindsey Muir; Research Assistant Professor, Computational Medicine and Bioinformatics; Partial Owner
- Walter Meixner; Research Laboratory Specialist Senior, Computational Medicine and Bioinformatics; Partial Owner

### Project #5

**Research Agreement between the University and Lysoway Therapeutics, Inc.  
Reviewed by the UMOR Conflict of Interest Review Committee**

#### Project Information

**Title:** Novel small molecule agonists of lysosomal TRPML1 in cancer therapy

**U-M Project ID:** 22-PAF06318

**Direct Sponsor:** Lysoway Therapeutics, Inc.

**Principal Investigator/Department:** Wanlu Du, Molecular, Cellular and Developmental Biology

**Project Duration:** One (1) Year

**Funding Support:** \$49,100

**Purpose:** The purpose of this pre-clinical project is to study the in vivo efficacy of the highly potent and specific synthetic agonists (ML-SAs) acting on TRPML1 (transient receptor potential mucolipin 1, or ML1), a Ca<sup>2+</sup> and Zn<sup>2+</sup> permeable cation channel predominantly localized on the membrane of lysosomes, on the xenograft mouse tumor models.

#### University Employee; University Title; Relationship with Lysoway Therapeutics, Inc.

- Haoxing Xu; Professor, Molecular, Cellular and Developmental Biology; Partial Owner

### Project #6

**STTR Phase I Subcontract Agreement between the University and Prevada Medical, Inc.  
Reviewed by the Medical School Conflict of Interest Board**

#### Project Information

**Title:** Development of a novel endotracheal tube mouthguard to prevent ventilator-associated pneumonia

**U-M Project ID:** 22-PAF04976

**Direct Sponsor:** Prevada Medical, Inc.

**Prime Sponsor:** National Institutes of Health

**Principal Investigator/Department:** J Scott VanEpps, Emergency Medicine

**Project Duration:** One (1) Year

**Funding Support:** \$158,071

**Purpose:** The purpose of this project is to develop a mouth guard accessory to standard endotracheal tubes (ETTs) that will reduce the risk of ventilator-associated pneumonia (VAP) in mechanically ventilated, intensive care unit (ICU) patients.

#### University Employee; University Title; Relationship with Prevada Medical, Inc.

- Kevin Ward; Professor, Emergency Medicine; Partial Owner

## Project #7

### Research Agreement between the University and The Hope Foundation Reviewed by the Medical School Conflict of Interest Board

#### Project Information

**Title:** Precision Targeting of Bladder Cancer Using CRISPR

**U-M Project ID:** 22-PAF05731

**Direct Sponsor:** The Hope Foundation

**Principal Investigator/Department:** Mats Ljungman, Radiation Oncology

**Project Duration:** Two (2) Years

**Funding Support:** \$250,000

**Purpose:** The purpose of this project is to specifically target chromosome rearrangement junctions (CRJs) in cancer cells.

#### University Employee; University Title; Relationship with The Hope Foundation

- James Rae; Professor, Internal Medicine-Hematology/Oncology; Board of Directors Officer